Clinical usefulness and reproducibility of histologic subclassification of advanced diffuse histiocytic lymphoma

James Olen Armitage, Fred R. Dick, Charles E. Platz, Michael P. Corder, Joseph T. Leimert

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Thirty-one patients with stage III and IV diffuse histiocytic lymphoma (DHL) were treated uniformly with cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP). The patients were subclassified independently by two hematopathologists into groups with predominantly large noncleaved cells (eight patients), predominantly large cleaved cells (seven patients), a mixture of large cleaved cells and large noncleaved cells (11 patients), tumors with the characteristics of immunoblastic sarcomas (two patients) and unclassified (three patients). The concurrence rate on applying the subclassification was 85 per cent. Survival in patients with large noncleaved cells was superior to that of the other patients as a group (p < 0.001), and to that of those with large cleaved cells (p < 0.05) and large cleaved and large noncleaved cells (p < 0.025). All the patients with large noncleaved cells are alive and "off" therapy without evidence of progressive disease. This histologic subclassification seems to identify a subgroup of patients with advanced diffuse histiocytic lymphoma having large noncleaved cells who have an excellent prognosis when treated with CHOP.

Original languageEnglish (US)
Pages (from-to)929-934
Number of pages6
JournalThe American Journal of Medicine
Volume67
Issue number6
DOIs
StatePublished - Jan 1 1979

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Large-Cell Immunoblastic Lymphoma
Vincristine
Cell- and Tissue-Based Therapy
Prednisone
Doxorubicin
Cyclophosphamide

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Clinical usefulness and reproducibility of histologic subclassification of advanced diffuse histiocytic lymphoma. / Armitage, James Olen; Dick, Fred R.; Platz, Charles E.; Corder, Michael P.; Leimert, Joseph T.

In: The American Journal of Medicine, Vol. 67, No. 6, 01.01.1979, p. 929-934.

Research output: Contribution to journalArticle

Armitage, James Olen ; Dick, Fred R. ; Platz, Charles E. ; Corder, Michael P. ; Leimert, Joseph T. / Clinical usefulness and reproducibility of histologic subclassification of advanced diffuse histiocytic lymphoma. In: The American Journal of Medicine. 1979 ; Vol. 67, No. 6. pp. 929-934.
@article{d00c3f67373b462d95e31beece328f87,
title = "Clinical usefulness and reproducibility of histologic subclassification of advanced diffuse histiocytic lymphoma",
abstract = "Thirty-one patients with stage III and IV diffuse histiocytic lymphoma (DHL) were treated uniformly with cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP). The patients were subclassified independently by two hematopathologists into groups with predominantly large noncleaved cells (eight patients), predominantly large cleaved cells (seven patients), a mixture of large cleaved cells and large noncleaved cells (11 patients), tumors with the characteristics of immunoblastic sarcomas (two patients) and unclassified (three patients). The concurrence rate on applying the subclassification was 85 per cent. Survival in patients with large noncleaved cells was superior to that of the other patients as a group (p < 0.001), and to that of those with large cleaved cells (p < 0.05) and large cleaved and large noncleaved cells (p < 0.025). All the patients with large noncleaved cells are alive and {"}off{"} therapy without evidence of progressive disease. This histologic subclassification seems to identify a subgroup of patients with advanced diffuse histiocytic lymphoma having large noncleaved cells who have an excellent prognosis when treated with CHOP.",
author = "Armitage, {James Olen} and Dick, {Fred R.} and Platz, {Charles E.} and Corder, {Michael P.} and Leimert, {Joseph T.}",
year = "1979",
month = "1",
day = "1",
doi = "10.1016/0002-9343(79)90632-6",
language = "English (US)",
volume = "67",
pages = "929--934",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Clinical usefulness and reproducibility of histologic subclassification of advanced diffuse histiocytic lymphoma

AU - Armitage, James Olen

AU - Dick, Fred R.

AU - Platz, Charles E.

AU - Corder, Michael P.

AU - Leimert, Joseph T.

PY - 1979/1/1

Y1 - 1979/1/1

N2 - Thirty-one patients with stage III and IV diffuse histiocytic lymphoma (DHL) were treated uniformly with cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP). The patients were subclassified independently by two hematopathologists into groups with predominantly large noncleaved cells (eight patients), predominantly large cleaved cells (seven patients), a mixture of large cleaved cells and large noncleaved cells (11 patients), tumors with the characteristics of immunoblastic sarcomas (two patients) and unclassified (three patients). The concurrence rate on applying the subclassification was 85 per cent. Survival in patients with large noncleaved cells was superior to that of the other patients as a group (p < 0.001), and to that of those with large cleaved cells (p < 0.05) and large cleaved and large noncleaved cells (p < 0.025). All the patients with large noncleaved cells are alive and "off" therapy without evidence of progressive disease. This histologic subclassification seems to identify a subgroup of patients with advanced diffuse histiocytic lymphoma having large noncleaved cells who have an excellent prognosis when treated with CHOP.

AB - Thirty-one patients with stage III and IV diffuse histiocytic lymphoma (DHL) were treated uniformly with cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP). The patients were subclassified independently by two hematopathologists into groups with predominantly large noncleaved cells (eight patients), predominantly large cleaved cells (seven patients), a mixture of large cleaved cells and large noncleaved cells (11 patients), tumors with the characteristics of immunoblastic sarcomas (two patients) and unclassified (three patients). The concurrence rate on applying the subclassification was 85 per cent. Survival in patients with large noncleaved cells was superior to that of the other patients as a group (p < 0.001), and to that of those with large cleaved cells (p < 0.05) and large cleaved and large noncleaved cells (p < 0.025). All the patients with large noncleaved cells are alive and "off" therapy without evidence of progressive disease. This histologic subclassification seems to identify a subgroup of patients with advanced diffuse histiocytic lymphoma having large noncleaved cells who have an excellent prognosis when treated with CHOP.

UR - http://www.scopus.com/inward/record.url?scp=0018612914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018612914&partnerID=8YFLogxK

U2 - 10.1016/0002-9343(79)90632-6

DO - 10.1016/0002-9343(79)90632-6

M3 - Article

VL - 67

SP - 929

EP - 934

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 6

ER -